ExoStemTech
Pioneering exosome-based therapeutics for osteoarthritis, liver fibrosis, and lung fibrosis with cutting-edge mass production technology.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | KRW10.0b | Series B | |
| Total Funding | 000k | ||
ExoStemTech is a biotechnology company specializing in the development of exosome-based therapeutics. The company focuses on creating treatments for various medical conditions, including osteoarthritis, liver fibrosis, and lung fibrosis. ExoStemTech operates in the biopharmaceutical market and serves clients such as healthcare providers, research institutions, and pharmaceutical companies. The company's business model revolves around the mass production and quality control of exosomes, which are small vesicles released by cells that can be used for therapeutic purposes. ExoStemTech generates revenue through the development and commercialization of its proprietary exosome therapies, as well as through partnerships and collaborations with other organizations in the healthcare sector. The company is currently advancing its lead asset for osteoarthritis treatment into phase 1 clinical trials and is developing a pipeline of over eight different therapeutics.
Keywords: exosome therapeutics, osteoarthritis, liver fibrosis, lung fibrosis, mass production, biotechnology, clinical trials, healthcare, biopharmaceutical, stem cell, quality control.